As of Jan 20
| +0.01 / +5.75%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 2.50, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a +1,258.70% increase from the last price of 0.18.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.